{"id":126865,"date":"2026-09-07T07:36:33","date_gmt":"2026-09-07T07:36:33","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/126865\/"},"modified":"2026-09-07T07:36:33","modified_gmt":"2026-09-07T07:36:33","slug":"novartis-shares-down-as-failed-cholesterol-drug-study-increases-pipeline-pressure","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/126865\/","title":{"rendered":"Novartis shares down as failed cholesterol drug study increases pipeline pressure"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">LONDON, Sept 7 (Reuters) &#8211; Shares of Novartis fell 3.3% on Monday \u200cmorning after its cholesterol \u200cdrug failed in a closely watched study, \u200bcasting fresh doubt on the therapeutic approach and raising the stakes for the Swiss drugmaker&#8217;s upcoming data \u200cfor a gene \u2060therapy.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Late on Friday, Novartis said its drug pelacarsen did \u2060not cut heart attack and stroke risk in a large, late-stage \u200bstudy of \u200bpatients with \u200bhigh Lp(a), an \u200cinherited, cholesterol-related risk factor with no approved targeted treatments.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The failure raises the bar for rival Lp(a)-lowering drugs from Amgen and Eli Lilly, \u200cboth running late-stage trials. \u200bIt also increases \u200bthe pressure \u200bon data from an \u200cexperimental muscular dystrophy drug \u200bdel-desiran, which \u200bNovartis spent $12 billion to acquire last year.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Analysts had modeled peak \u200bannual sales \u200cbetween $3 billion and $6 billion for \u200bpelacarsen.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">(Reporting by Bhanvi Satija; Editing \u200bby Joe Bavier)  <\/p>\n","protected":false},"excerpt":{"rendered":"LONDON, Sept 7 (Reuters) &#8211; Shares of Novartis fell 3.3% on Monday \u200cmorning after its cholesterol \u200cdrug failed&hellip;\n","protected":false},"author":2,"featured_media":126866,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[61938,61936,9258,4396,216,61934,61937,61935,996,2282,206,5199,61939,41],"class_list":["post-126865","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-3-3","tag-bhanvi-satija","tag-both","tag-drug","tag-eli-lilly","tag-experimental","tag-inherited","tag-joe-bavier","tag-london","tag-monday","tag-novartis","tag-reuters","tag-sept-7","tag-swiss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117228613569455358","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/126865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=126865"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/126865\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/126866"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=126865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=126865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=126865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}